Anti-Human CD20 Reference Antibody (Rituximab, RUO)
- Catalog number: BS12213
- Availability: In Stock
$370.00
- Ex Tax: $370.00
Description: Rituximab (BS12213) is a research-grade recombinant antibody targeting CD20. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: B-lymphocytesurfaceantigenB1,Membrane-spanning4-domainssubfamilyAmember1,MS4A1,LeukocytesurfaceantigenLeu-16,B-lymphocyteantigenCD20,Bp35,CD20
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names:
Background: B-lymphocyte antigen CD20 (MS4A1) is a ~33 kDa protein. B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. CD20 is the therapeutic target of rituximab (MabThera) and obinutuzumab (Gazyva).
References:
1. Li, H. et al. (2003) The Journal of biological chemistry 278, 42427-34. PMID: 12920111
2. Tedder, TF. et al. (1985) Journal of immunology (Baltimore, Md. : 1950) 135, 973-9. PMID: 3925015
3. Bubien, JK. et al. (1993) The Journal of cell biology 121, 1121-32. PMID: 7684739
4. Polyak, MJ. et al. (2008) The Journal of biological chemistry 283, 18545-52. PMID: 18474602
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: B-lymphocytesurfaceantigenB1,Membrane-spanning4-domainssubfamilyAmember1,MS4A1,LeukocytesurfaceantigenLeu-16,B-lymphocyteantigenCD20,Bp35,CD20
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names:
Background: B-lymphocyte antigen CD20 (MS4A1) is a ~33 kDa protein. B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes. Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR. CD20 is the therapeutic target of rituximab (MabThera) and obinutuzumab (Gazyva).
References:
1. Li, H. et al. (2003) The Journal of biological chemistry 278, 42427-34. PMID: 12920111
2. Tedder, TF. et al. (1985) Journal of immunology (Baltimore, Md. : 1950) 135, 973-9. PMID: 3925015
3. Bubien, JK. et al. (1993) The Journal of cell biology 121, 1121-32. PMID: 7684739
4. Polyak, MJ. et al. (2008) The Journal of biological chemistry 283, 18545-52. PMID: 18474602
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
SDS-PAGESDS-PAGE for Research Grade Lunsekimig.
